Eli Lilly yesterday announced a partnership with U. K. drug maker AstraZeneca to develop and commercialize a potential new drug for Alzheimer’s. AstraZeneca will produce the drug, ASD3293, and Lilly will lead the clinical trials. The drug is one of a class of drugs called BASE inhibitors. BASE inhibitors inhibit an enzyme, beta-secretase, which is involved in forming the plaques …
Read More »